What's Happening?
Altesa BioSciences has presented new data at the 2026 International Conference on Antiviral Research, demonstrating that its antiviral drug, vapendavir, is effective against Rhinovirus C (RV-C). The research, which includes clinical, computational, and
laboratory studies, shows that vapendavir and its active metabolite ALT-001 inhibit RV-C at clinically relevant concentrations. This finding challenges previous assumptions about the treatability of RV-C with capsid inhibitors. Vapendavir is currently being evaluated in a Phase 2b study for COPD patients experiencing rhinovirus infections.
Why It's Important?
The development of vapendavir as a treatment for rhinovirus infections is significant because rhinovirus is a major cause of acute exacerbations in chronic lung diseases like COPD. Current treatments focus on managing symptoms rather than addressing the underlying viral cause. Vapendavir's ability to inhibit RV-C could represent a breakthrough in preemptive treatment options for respiratory infections, potentially improving outcomes for patients with COPD and other chronic lung conditions. This advancement could also lead to broader applications in treating other high-risk respiratory populations.
What's Next?
Altesa BioSciences is moving forward with the Phase 2b CARDINAL study, which will enroll 900 COPD patients in the US and UK. The study aims to assess the improvement in respiratory symptoms and other health outcomes. The results of this trial will be crucial in determining vapendavir's efficacy and potential as a new treatment option. If successful, vapendavir could become a key player in the respiratory antiviral market, offering a new approach to managing viral infections in vulnerable patient populations.
